Renal medicine, Kolling Institute, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales 2065, Australia.
School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, New South Wales 2007, Australia.
Nutrients. 2019 Jan 11;11(1):146. doi: 10.3390/nu11010146.
Maternal obesity has been associated with kidney disorders in male offspring. Our previous studies have demonstrated that Sirtuin (SIRT)1, an essential regulator of metabolic stress responses, is suppressed in the offspring as the result of maternal high-fat diet (HFD) consumption, which is likely to underpin the adverse metabolic and renal outcomes. To examine if SIRT1 overexpression or activation early in life can protect the offspring kidney, wild-type (WT) and transgenic (Tg) offspring were born to the same diet-induced obese female C57BL/6 mice through breeding with hemizygous SIRT1-transgenic (Tg) male mice and examined for renal pathological changes. In separate experiments, SIRT1 activator SRT1720 (25 mg/kg/2 days i.p) was administrated in WT offspring over 6 weeks of postnatal high-fat diet exposure. The results show that offspring born to obese dams have increased kidney weight, higher levels of renal triglycerides, and increased expression of oxidative stress, inflammatory, and fibrotic markers, as well as increased albuminuria compared to offspring of control dams. Both SIRT1 overexpression and SRT1720 treatment attenuated renal lipid contents and expression of lipogenesis, oxidative stress, and inflammatory markers; however, fibrosis was modestly reduced and albuminuria was not affected. The findings suggest that SIRT1 therapy can ameliorate some pathological mechanisms of kidney programming due to maternal obesity but may not be sufficient to prevent the resulting chronic kidney injury.
母体肥胖与雄性后代的肾脏疾病有关。我们之前的研究表明,Sirtuin (SIRT)1 是代谢应激反应的重要调节因子,由于母体高脂肪饮食 (HFD) 的消耗而在后代中受到抑制,这可能是导致代谢和肾脏不良后果的原因。为了研究 SIRT1 早期过表达或激活是否可以保护后代的肾脏,我们通过与半合子 SIRT1 转基因 (Tg) 雄性小鼠杂交,使 WT 和 Tg 后代在相同的饮食诱导肥胖的 C57BL/6 母鼠中出生,并检查其肾脏病理变化。在单独的实验中,SIRT1 激活剂 SRT1720(25 mg/kg/2 天腹腔注射)在 WT 后代中进行了 6 周的高脂肪饮食暴露。结果表明,与对照母鼠的后代相比,肥胖母鼠所生的后代肾脏重量增加,肾脏甘油三酯水平升高,氧化应激、炎症和纤维化标志物表达增加,以及蛋白尿增加。SIRT1 过表达和 SRT1720 治疗均减轻了肾脏脂质含量和脂肪生成、氧化应激和炎症标志物的表达;然而,纤维化略有减少,蛋白尿不受影响。这些发现表明,SIRT1 治疗可以改善由于母体肥胖引起的肾脏编程的一些病理机制,但可能不足以预防由此导致的慢性肾脏损伤。